2024 CBIIC in Guangzhou on November 30 - December 1, 2024.

LU Xianping

Dr. Lu returned to China in September 2000 to take up a position as a senior visiting scholar at the State Key Laboratory of Membrane Biology at Tsinghua University. After founding Chipscreen Biosciences in 2001, he has successively served as the Chief Scientific Officer, President, Deputy Chairman, and Chairman of Chipscreen Biosciences.

Dr. Lu graduated with a BSc in biochemistry from Sichuan University in 1983 and PhD in molecular biology from Peking Union Medical College, Chinese Academy of Medical Sciences in 1988. He pursued postdoctoral training at the University of California, San Diego (UCSD) in 1989 and co-founded Maxia Pharmaceuticals and Galderma Research Inc. in San Diego in 1994, serving as Director of Research at Galderma R&D. With more than 30 years of global experience in drug research, development and management, Dr. Lu is highly accomplished in the fields of molecular medicine, oncology, neuroendocrinology, immunity, metabolism and skin diseases. He has published more than 100 articles in top international journals such as Science, Nature, and Lancet, and is named as the first inventor on over 100 invention patents in the field of drug discovery.